Introduction {#Sec1}
============

Nonvalvular atrial fibrillation (NVAF) is a cardiac rhythm disorder, which increases stroke risk approximately fivefold and affects \>5 million Americans \[[@CR1], [@CR2]\]. Warfarin is efficacious for reducing stroke risk among NVAF patients, but its use has limitations, including a narrow therapeutic range, significant drug--drug interactions, and an increased risk for major bleeding events, all of which can be exacerbated for those with comorbidities and/or who are ≥75 years of age \[[@CR3], [@CR4]\]. The Apixaban for the Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY), and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trials demonstrated that the oral anticoagulants (OACs), apixaban, dabigatran (150 mg), and rivaroxaban, respectively, are at least as efficacious as warfarin for stroke prevention among NVAF patients \[[@CR5]--[@CR7]\]. NVAF patients included in these trials differed in stroke risk from those in the ROCKET-AF trial in having a mean CHADS~2~ score of 3.5, while those included in the other trials had mean CHADS~2~ scores of 2.1 \[[@CR5]--[@CR7]\]. Medical costs for clinical events among the overall NVAF population using any of the OACs vs. warfarin were estimated to be lower \[[@CR8]\]. However, these results may differ for patients with different stroke risks. This study compared medical costs for clinical events of NVAF patients in the OAC vs. warfarin trials with moderate (CHADS~2~ = 2) and higher stroke risk (CHADS~2~ ≥ 3) treated with individual OACs vs. warfarin from a US payer perspective.

Materials and methods {#Sec2}
=====================

Clinical event rates (stroke/systemic embolism (SSE), myocardial infarction (MI), pulmonary embolism/deep vein thrombosis (PE/DVT), major bleeding events excluding hemorrhagic stroke (MBEHS), non-major bleeding events) among NVAF patients with CHADS~2~ = 2 and ≥3 treated with individual OACs or warfarin were determined from the three OAC trials \[[@CR5]--[@CR7]\] (Table [1](#Tab1){ref-type="table"}). Hemorrhagic stroke (HS) was considered as an efficacy and safety end point in the OAC vs. warfarin trials. To avoid costing twice, HS events were excluded from major bleeding events, but kept grouped with SSE. MBEHS rate was defined as the absolute event rate of major bleeding events minus HS. When the event rate for a particular clinical event was not reported in a clinical trial, the rate of an end point containing this clinical event was used \[[@CR8]\]. The event rates of non-major bleeding events, including clinically relevant non-major bleeding events and other minor bleeding events, were not reported by stroke risk groups in the original clinical trial publications. In this analysis we assumed the relative risks of these non-major bleeding events for NVAF patients with different stroke risks to be the same as those for major bleeding events reported for each trial. These estimated relative risks of non-major bleeding events in combination with the absolute event rates of non-major bleeding events from the overall trial population were used to estimate the event rates of non-major bleeding events for the stroke risk groups. The event rates of the secondary end points, MI, and PE/DVT were assumed to be the same as those of the overall trial population since such stroke risk group-specific data were not reported in the OAC vs. warfarin clinical trials.Table 1Estimated absolute risks for clinical events among NVAF patients at moderate and high stroke riskTrialARISTOTLERE-LYROCKET-AFDrugWarfarin (%/patient-year)Apixaban (%/patient-year)Warfarin (%/patient-year)Dabigatran (%/patient-year)Warfarin (%/patient-year)Rivaroxaban (%/patient-year)CHADS~2~=2≥3=2≥3=2≥3=2≥3=2≥3=2≥3SSE1.402.801.201.901.382.680.841.882.152.441.792.15MI^a^0.610.610.530.530.530.530.740.741.121.120.910.91PE/DVT^a^0.050.050.040.040.090.090.150.15NRNRNRNRMBEHS2.593.392.082.553.004.012.974.693.292.854.263.13Non-major bleeding events^b^22.7122.7117.4115.6816.3716.3715.0317.2613.4313.4316.3113.87*ARISTOTLE* apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, *MBEHS* major bleeding events excluding hemorrhagic stroke, *MI* myocardial infarction, *NR* not reported, *NVAF* nonvalvular atrial fibrillation, *PE/DVT* pulmonary embolism/deep vein thrombosis, *RE*-*LY* randomized evaluation of long-term anticoagulation therapy, *ROCKET*-*AF* rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation^a^Rates of MI and PE/DVT were not reported by CHADS~2~ score and those from the overall trial population were used \[[@CR8]\]^b^Relative risks of non-major bleeding events were assumed to be the same as major bleeding events in each trial, and these in combination with absolute event rates of non-major bleeding events from the overall trial populations were used for estimations of event rates

One-year incremental costs (US payer perspective) for clinical events were obtained and adjusted to 2010 costs \[[@CR8], [@CR9]\]. Based on the absolute risks for each of the clinical events, differences in medical costs associated with each OAC vs. warfarin were determined. Drug costs and monitoring expenses were not evaluated.

We additionally carried out a sensitivity analysis in which rates of clinical events for warfarin-treated NVAF patients were estimated as weighted averages from the three OAC trials by patient count. The absolute risks of events associated with OACs were derived by applying trial relative risks to the weighted average of warfarin event rates producing event rate estimates for each OAC for NVAF patients with CHADS~2~ = 2 and CHADS~2~ ≥3.

The authors conformed to the Helsinki Declaration of 1975, as revised in 2000 concerning human and animal rights, and Springer's policy concerning informed consent has been followed.

Results {#Sec3}
=======

One-year medical costs of clinical events were as follows: SSE = \$40,613 \[[@CR10], [@CR11]\], MI = \$37,446 \[[@CR12]\], PE/DVT = \$19,532 \[[@CR13]\], MBEHS = \$34,617 \[[@CR10]\], non-major bleeding event = \$130 \[[@CR8], [@CR14]\]. In a year, overall medical cost differences associated with apixaban, dabigatran, and rivaroxaban use relative to warfarin among NVAF patients with CHADS~2~ = 2 were estimated at −\$298, −\$143, and \$117, respectively (negative numbers indicate cost reduction), and among those with CHADS~2~ ≥ 3 were estimated at −\$697, \$2, and −\$100, respectively (Table [2](#Tab2){ref-type="table"}).Table 2Estimated differences in medical costs for clinical events among NVAF patients at moderate and high stroke riskTrialARISTOTLERE-LYROCKET-AFDrugApixaban (\$/patient-year)Dabigatran (\$/patient-year)Rivaroxaban (\$/patient-year)CHADS~2~=2≥3=2≥3=2≥3SSE−\$81−\$366−\$219−\$325−\$143−\$119MI−\$30−\$30\$79\$79−\$79−\$79PE/DVT−\$2−\$2\$12\$12NRNRMBEHS−\$178−\$290−\$13\$236\$334\$97Non-major bleeding events−\$7−\$9−\$2\$1\$4\$1Total−\$298−\$697−\$143\$2\$117−\$100*ARISTOTLE* apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, *MBEHS* major bleeding events excluding hemorrhagic stroke, *MI* myocardial infarction, *NR* not reported, *NVAF* nonvalvular atrial fibrillation, *PE/DVT* pulmonary embolism/deep vein thrombosis, *RE*-*LY* randomized evaluation of long-term anticoagulation therapy, *ROCKET*-*AF* rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation

In the sensitivity analysis, in which rates of clinical events for warfarin were estimated as weighted averages from the three OAC trials and those of individual OACs as relative risks to the common warfarin event rates, overall medical cost differences associated with apixaban, dabigatran, and rivaroxaban use relative to warfarin among NVAF patients with CHADS~2~ = 2 were estimated at −\$332, −\$151, and \$135, respectively, and among those with CHADS~2~ ≥ 3 were estimated at −\$664, \$0, and −\$63, respectively (Table [3](#Tab3){ref-type="table"}).Table 3Sensitivity analysis: estimated differences in medical costs for clinical events among NVAF patients at moderate and high stroke riskTrialARISTOTLERE-LYROCKET-AFDrugApixaban (\$/patient-year)Dabigatran (\$/patient-year)Rivaroxaban (\$/patient-year)CHADS~2~=2≥3=2≥3=2≥3SSE−\$87−\$366−\$239−\$312−\$100−\$126MI−\$35−\$35\$79\$79−\$56−\$56PE/DVT−\$3−\$3\$8\$8−\$2−\$2MBEHS−\$201−\$282\$3\$224\$287\$119Non-major bleeding events−\$5−\$7−\$2\$1\$5\$1Total−\$332−\$664−\$151\$0\$135−\$63*ARISTOTLE* apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, *MBEHS* major bleeding events excluding hemorrhagic stroke, *MI* myocardial infarction, *NR* not reported, *NVAF* nonvalvular atrial fibrillation, *PE/DVT* pulmonary embolism/deep vein thrombosis, *RE*-*LY* randomized evaluation of long-term anticoagulation therapy, *ROCKET*-*AF* rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation

Discussion {#Sec4}
==========

Differences in medical costs for OACs compared with warfarin are dependent on the specific OAC used and stroke risk. In this analysis, only apixaban use was associated with consistently reduced medical costs relative to warfarin for NVAF patients with moderate or high stroke risk. The primary drivers for medical cost reductions associated with apixaban use, relative to warfarin, were reduced rates of SSE, which were 14% and 32% lower, and MBEHS, which were 20% and 25% lower, for NVAF patients with CHADS~2~ = 2 and CHADS~2~ ≥ 3, respectively. The use of either dabigatran or rivaroxaban instead of warfarin was associated with lower risks for SSE, but not consistently lower risks for other clinical events and, therefore, their cost differences were less.

This analysis was based on clinical trial data and the application of the results to routine clinical practice requires further assessment. Since the occurrences of stroke and major bleeding events may be greater in routine clinical practice \[[@CR15]\], the cost differences may have been underestimated. Additionally, when major bleeding events and HS relative rates were originally reported as hazard ratios, the analysis measured the relative risk of "time to first event" \[[@CR5]--[@CR7]\]. The subtraction approach used in this analysis did not consider any impact of timing and, thus, may have underestimated the rate of MBEHS.
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